| Full text | |
| Author(s): |
Buccheri, Renata
[1]
;
Kassab, Maria Jose
[1]
;
Teixeira de Freitas, Vera Lucia
[2, 3]
;
Vicente da Silva, Sheila Cristina
[3]
;
Bezerra, Rita C.
[4]
;
Khoury, Zarifa
[1]
;
Shikanai-Yasuda, Maria Aparecida
[2, 3]
;
Vidal, Jose E.
[1]
Total Authors: 8
|
| Affiliation: | [1] Inst Infectol Emilio Ribas, BR-01246900 Sao Paulo, SP - Brazil
[2] Univ Sao Paulo, Fac Med, Dept Molestias Infecciosas & Parasitarias, BR-05508 Sao Paulo, SP - Brazil
[3] Univ Sao Paulo, Hosp Clin, Lab Invest Med Imunol LIM 48, BR-05508 Sao Paulo, SP - Brazil
[4] Univ Sao Paulo, Hosp Clin, Lab Invest Med Parasitol LIM 46, BR-05508 Sao Paulo, SP - Brazil
Total Affiliations: 4
|
| Document type: | Journal article |
| Source: | Revista do Instituto de Medicina Tropical de São Paulo; v. 57, n. 6, p. 531-535, NOV-DEC 2015. |
| Web of Science Citations: | 0 |
| Abstract | |
The reactivation of Chagas disease in HIV infected patients presents high mortality and morbidity. We present the case of a female patient with confirmed Chagasic meningoencephalitis as AIDS-defining illness. Interestingly, her TCD4+ lymphocyte cell count was 318 cells/mm3. After two months of induction therapy, one year of maintenance with benznidazol, and early introduction of highly active antiretroviral therapy (HAART), the patient had good clinical, parasitological and radiological evolution. We used a qualitative polymerase chain reaction for the monitoring of T. cruzi parasitemia during and after the treatment. We emphasize the potential value of molecular techniques along with clinical and radiological parameters in the follow-up of patients with Chagas disease and HIV infection. Early introduction of HAART, prolonged induction and maintenance of antiparasitic therapy, and its discontinuation are feasible, in the current management of reactivation of Chagas disease. (AU) | |
| FAPESP's process: | 12/50273-0 - Monitoring of immunossupressed patients with Chagas Disease, response levels of parasitemia and associate with cytokines profile and polymorphism and patient survival and Trypanosoma cruzi isolate characteristics under organ transplant, immunosuppressive drugs |
| Grantee: | Maria Aparecida Shikanai Yasuda |
| Support Opportunities: | Regular Research Grants |